An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting (2024)

Vora JP, Ibrahim HA, Bakris GL . Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. J Hum Hypertens 2000; 14: 667–685.

Article CAS Google Scholar

UK Renal Registry Report 2002. UK Renal Registry: Bristol, 2002, http://www.renalreg.com/Slides2002/Report%202002.pdf

Stengel B et al. Trends in the incidence of renal replacement therapy for end–stage renal disease in Europe, 1990–1999. Nephrol Dial Transplant 2003; 18: 1824–1833.

Article Google Scholar

Lamping DL et al. Clinical outcomes, quality of life, and costs in the North Thames Dialysis Study of elderly people on dialysis: a prospective cohort study. Lancet 2000; 356: 1543–1550.

Article CAS Google Scholar

Lewis EJ et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.

Article CAS Google Scholar

Rodby RA et al. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther 2003; 25: 2103–2119.

Article Google Scholar

Palmer AJ et al. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy; cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian, and French settings. Nephrol Dial Transplant 2003; 18: 2059–2066.

Article CAS Google Scholar

Palmer AJ et al. Gesundheitsökonomische Aspekte der Anwendung von Irbesartan in Deutschland. [Health economic consequences of irbesartan treatment of type 2 diabetes patients with hypertension and nephropathy in Germany. Dtsch Med Wochenschr 2004; 129: 13–18.

Article CAS Google Scholar

Naimark D et al. Primer on medical decision analysis: Part 5—Working with Markov processes. Med Decis Making 1997; 17: 152–159.

Article CAS Google Scholar

Palmer AJ et al. The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective. Diabetologia 1999; 43: 13–26.

Article Google Scholar

Bagust A et al. An economic model of the long-term health care burden of Type II diabetes. Diabetologia 2001; 44: 2140–2155.

Article CAS Google Scholar

British National Formulary (BNF 45, March 2003). British Medical Association, Royal Pharmaceutical Society of Great Britain. Pharmaceutical Press: Oxford UK, 2003.

Clarke P et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003; 20: 442–450.

Article CAS Google Scholar

NHS R&D Health Technology Assessment 1998. Vol. 2(5), 1998.

NHS R&D Health Technology Assessment 2003. Vol. 7 (2), 2003.

Lamping DL et al. Clinical outcomes, quality of life, and costs in the North Thames Dialysis Study of elderly people on dialysis: a prospective cohort study. Lancet 2000; 356 (9241): 1543–1550.

Article CAS Google Scholar

NICE. National Institute for Clinical Excellence. Technical Guidance for Manufacturers and Sponsors on Making a Submission to a Technology Appraisal. National Institute for Clinical Excellence: London, 2001, www.nice.org.uk/Docref.asp?d=16183.

Gozzoli V et al. (Increased clinical and economic advantages using PROSIT (proteinuria screening and intervention) in type 2 diabetic patients). Dtsch Med Wochenschr 2000; 125: 1154–1159.

Article CAS Google Scholar

Clarke P et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No 51). Diabetologia 2001; 44: 298–304.

Article CAS Google Scholar

UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.

Gerth WC et al. Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union. Kidney Int 2002; 62(Suppl 82): 68–72.

Article Google Scholar

Herman WH et al. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Diabetes Care 2003; 26: 683–687.

Article Google Scholar

Willke RJ, Glick HA, Polsky D, Schulman K . Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ 1998; 7: 481–493.

Article CAS Google Scholar

Kjeldsen SE et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491–1498.

Article CAS Google Scholar

Hendry BM et al. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients. QJM 1997; 90: 277–282.

Article CAS Google Scholar

Adler AI et al. Development and progression of nephropathy in Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225–232.

Article Google Scholar

NHS UK Transplant December 2002, http://www.uktransplant.org.uk/newsroom/fact_sheets/cost_effectiveness_of_transplantation.htm.